Site's Items (Sorted by Submit Date in Descending order): 21 to 40 of 722
| Publication Year | Title | Author(s) |
| 2009 | Failure to achieve a threshold dose of CD34+CD110+ progenitor cells in the graft predicts delayed platelet engraftment after autologous stem cell transplantation for multiple myeloma | Wallington-Gates, Craig ; Gottlieb, DJ; Garvin, F; Antonenas, V; Sartor, MM |
| 2012 | Disparate in vivo efficacy of FTY720 in xenograft models of Philadelphia positive and negative B-lineage acute lymphoblastic leukemia | Wallington-Gates, Craig ; Campbell, Don ; Hewson, J; Qiao, Q; Papa, RA; Lock, RB; Bradstock, KF; Bendall, LJ |
| 2019 | PS1383 A SEQUENTIAL COHORT STUDY COMPARING KAPPAMAB ALONE TO KAPPAMAB, LENALIDOMIDE AND LOW DOSE DEXAMETHASONE IN KAPPA-RESTRICTED RELAPSED REFRACTORY (RR) MULTIPLE MYELOMA (AMARC 01–16) | Craig Wallington-Gates |
| 2022 | Secondary Analysis of the MM21 Trial: Response Adaptive Salvage Treatment with Daratumumab-Lenalidomide-Dexamethasone (DRd) for Newly Diagnosed Transplant Eligible Multiple Myeloma Patients Failing Front-Line Bortezomib-Based Induction Therapy | Sueh-li Lim; John Reynolds; Hang Quach; Anna Hutchinson; Ian H Kerridge; Jane Estell; Wallington-Gates, Craig ; Anna Kalff; Flora Yuen; Andrew Spencer |
| 2018 | Sphingosine Kinase 2 Supports the Development of BCR/ABL-Independent Acute Lymphoblastic Leukemia in Mice | Xie, V; Tong, D; Wallington-Gates, Craig Thomas  ; Bradstock, KF; Bendall, LJ |
| 2017 | Targeting Sphingosine Kinase 1 in Acute Myeloid Leukemia: Translation to the Clinic | Powell, JA; Wallington-Gates, Craig Thomas ; Pitson, SM |
| 2019 | Resistance Mechanisms to Novel Therapies in Myeloma | Wallington-Gates, Craig Thomas ; Coghlan, DW |
| 2018 | Targeting Sphingolipid Metabolism as an Approach for Combination Therapies in Haematological Malignancies | Lewis, AC; Wallington-Gates, Craig Thomas ; Powell, JA; Pitson, SM |
| 2018 | Resistance to Proteasome Inhibitors and other Targeted Therapies in Myeloma | Wallington-Gates, Craig Thomas ; Sobieraj-Teague, M; Kuss, BJ; Pitson, SM |
| 2021 | Clinical Outcomes in Patients (Pts) with Dose Reduction of Selinexor in Combination with Bortezomib, and Dexamethasone (XVd) in Previously Treated Multiple Myeloma from the Boston Study | Sundar Jagannath; Thierry Facon; Ashraf Z. Badros; Moshe Levy; Philippe Moreau; Sosana Delimpasi; Maryana Simonova; Ivan Spicka; Iryna Kriachok; Maria Gavriatopoulou; Halyna Pylypenko; Holger W Auner; Xavier Leleu; Vadim Doronin; Ganna Usenko; Roman Hajek; Reuben Benjamin; Tuphan Kanti Dolai; Dinesh Kumar Sinha; Chris P. Venner,; Mamta Garg; Mercedes Gironella Mesa; Artur Jurczyszyn; Tadeusz Robak; Monica Galli; Wallington-Gates, Craig Thomas ; Atanas Radinoff; Galina Salogub; Don Stevens; Supratik Basu; Anna Marina Liberati; Hang Quach; Veselina S Goranova Marinova; Jelena Sreten Bila; Eirini Katodritou; Andrew DeCastro; Yi Chai; Dane R. Van Domelen; Moran Mishal; Ohad S. Bentur; Jatin Shah; Sharon Shacham; Michael G. Kauffman; Sebastian Grosicki; Paul G. Richardson |
| Jul-2011 | FTY720 produces caspase-independent cell death of acute lymphoblastic leukemia cells | Wallington-Gates, Craig ; Hewson, John; Bradstock, Kenneth F; Bendall, Linda J |
| 2019 | Identification of Sphingosine Kinase 1 as a Therapeutic Target in B-lineage Acute Lymphoblastic Leukemia | Wallington-Gates, Craig ; Xie, V; Tong, D; Powell, JA; Lewis, A; Davies, L; Pitson, SM; Bradstock, KF; Bendall, LJ |
| 2010 | FTY720 Has Potent Anti-Leukemic Effects on Acute Lymphoblastic Leukemia Cells and Results In Caspase Independent Cell Death | Craig Wallington-Gates ; John Hewson; Kenneth Bradstock; Linda Bendall |
| 2019 | A Phase 2 trial of the combination of Ixazomib, Thalidomide and Dexamethasone (ITD) in relapsed and/or refractory multiple myeloma | Krystal Bergin; Flora Yuen; Craig Wallington-Gates ; Anna Kalff; Shreerang Sirdesai; John Reynolds; Andrew Spencer |
| 2021 | Author Correction: Targeting sphingolipid metabolism as an approach for combination therapies in haematological malignancies | Craig Wallington-Gates |
| 2021 | Mechanisms Driving Resistance to Proteasome Inhibitors Bortezomib, Carfilzomib, and Ixazomib in Multiple Myeloma | Craig Wallington-Gates |
| 2021 | Preliminary Analysis of the MM21 Trial: Response Adaptive Salvage Treatment with Daratumumab-Lenalidomide-Dexamethasone (DRd) for Newly Diagnosed Transplant Eligible Multiple Myeloma Patients Failing Front-Line Bortezomib-Based Induction Therapy | Craig Wallington-Gates |
| 2021 | The Effect of Daratumumab, Lenalidomide, Dexamethasone (DRd) on Peripheral Blood Stem Cell Mobilisation (PBSC) | Craig Wallington-Gates ; Tishya Indran; Michael Swain; Jacqueline Widjaja; Flora Yuen; Hang Quach; Wojt Janowski; Anna Hutchinson; Jane Estell; Ian H Kerridge; Andrew Spencer |
| 2019 | A Sequential Cohort Study Comparing Kappamab Alone to Kappamab, Lenalidomide and Low Dose Dexamethasone in Kappa-Restricted Relapsed Refractory Multiple Myeloma (AMaRC 01-16) | Anna Kalff; Jake Shortt; Flora Yuen; John Reynolds; Hang Quach; Craig Wallington-Gates ; Patricia Walker; Simon Harrison; Dunn Rosanne; Andrew Spencer |
| 2024 | Daratumumab, cyclophosphamide, bortezomib and dexamethasone for non-transplant eligible myeloma (AMaRC 03-16) | Mollee, Peter ; John Reynolds; Wojt Janowski; HANG QUACH; Philip Campbell; Simon Gibbs; Sophie Lee; Edwin Lee; Kerry Taylor; Cochrane, Tara ; Craig Wallington-Gates ; Fiona Kwok; Weber, Nicholas ; Ian Kerridge; Weston, Helen ; P Joy Ho; Michael Francis Leahy; Noemi Horvath; Andrew Spencer |
Site's Items (Sorted by Submit Date in Descending order): 21 to 40 of 722
